Skip to main content

Lateral Canthal Lines

3
Pipeline Programs
4
Companies
5
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Ipsen
DYSPORTApproved
botulinum toxin type a
Ipsen
Acetylcholine Release Inhibitor [EPC]injection2009
3M Part D

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Ipsen
IpsenChina - Tianjin
1 program
1
Botulinum toxin type APHASE_21 trial
Active Trials
NCT00247559Completed221Est. Apr 2005
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
botulinum toxin Type APhase 31 trial
Botulinum Toxin Type AN/A1 trial
Active Trials
NCT02248844Completed667Est. Aug 2017
NCT02195687Completed417Est. Jun 2015
Galderma
GaldermaTX - Dallas
1 program
1
botulinum toxinPhase 31 trial
Active Trials
NCT04249687Completed303Est. Feb 2021
Croma-Pharma
Croma-PharmaAustria - Leobendorf
1 program
Princess® RICHN/A1 trial
Active Trials
NCT03923634Completed102Est. Oct 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Galdermabotulinum toxin
AbbViebotulinum toxin Type A
IpsenBotulinum toxin type A
Croma-PharmaPrincess® RICH
AbbVieBotulinum Toxin Type A

Clinical Trials (5)

Total enrollment: 1,710 patients across 5 trials

NCT04249687Galdermabotulinum toxin

Treatment of Moderate to Severe Lateral Canthal Lines

Start: Feb 2020Est. completion: Feb 2021303 patients
Phase 3Completed
NCT02195687AbbViebotulinum toxin Type A

BOTOX® in the Treatment of Crow's Feet Lines in China

Start: Sep 2014Est. completion: Jun 2015417 patients
Phase 3Completed
NCT00247559IpsenBotulinum toxin type A

Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)

Start: May 2004Est. completion: Apr 2005221 patients
Phase 2Completed

Princess® RICH for the Correction of Fine Lines

Start: Oct 2018Est. completion: Oct 2019102 patients
N/ACompleted
NCT02248844AbbVieBotulinum Toxin Type A

Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea

Start: Sep 2014Est. completion: Aug 2017667 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.